{"context":{"query":">>mondo>>gwas_study","source_dataset":"mondo","target_dataset":"gwas_study"},"stats":{"queried":1,"total":39,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|first_author|journal|publication_date","mappings":[{"input":"MONDO:0004986","source":"MONDO:0004986|urinary bladder carcinoma","targets":["GCST000231|Urinary bladder cancer|Kiemeney LA|Nat Genet|2008-09-14","GCST000454|Bladder cancer|Wu X|Nat Genet|2009-08-02","GCST000639|Urinary bladder cancer|Kiemeney LA|Nat Genet|2010-03-28","GCST000842|Bladder cancer|Rothman N|Nat Genet|2010-10-24","GCST001153|Bladder cancer|Rafnar T|Hum Mol Genet|2011-07-12","GCST001193|Bladder cancer|Garcia-Closas M|Hum Mol Genet|2011-08-08","GCST002240|Bladder cancer|Figueroa JD|Hum Mol Genet|2013-10-24","GCST002243|Bladder cancer|Figueroa JD|Hum Mol Genet|2013-10-24","GCST002397|Bladder cancer (smoking interaction)|Figueroa JD|Carcinogenesis|2014-03-24","GCST002460|Urinary bladder cancer|Rafnar T|Hum Mol Genet|2014-05-26","GCST002645|Bladder cancer|Matsuda K|Hum Mol Genet|2014-10-03","GCST003384|Bladder cancer|Wang M|Cancer Res|2016-03-29","GCST008216|Non-muscle-invasive bladder cancer tumour size|Lipunova N|Eur Urol Oncol|2018-09-15","GCST008217|Non-muscle-invasive bladder cancer age at diagnosis|Lipunova N|Eur Urol Oncol|2018-09-15","GCST008218|Non-muscle-invasive bladder cancer age at diagnosis (< 70 years vs ≥ 70 years)|Lipunova N|Eur Urol Oncol|2018-09-15","GCST008219|Non-muscle-invasive bladder cancer tumour size (< 3 cm vs ≥ 3 cm)|Lipunova N|Eur Urol Oncol|2018-09-15","GCST008220|Non-muscle-invasive bladder cancer tumour stage (Tis/T1 vs Ta)|Lipunova N|Eur Urol Oncol|2018-09-15","GCST008221|Non-muscle-invasive bladder cancer tumour grade (G3 vs G2/G1)|Lipunova N|Eur Urol Oncol|2018-09-15","GCST008222|Non-muscle-invasive bladder cancer EORTC risk category|Lipunova N|Eur Urol Oncol|2018-09-15","GCST009872|Bladder cancer|Wu J|Front Oncol|2020-02-11","GCST90011817|Bladder cancer|Rashkin SR|Nat Commun|2020-09-04","GCST90041857|Malignant neoplasm of bladder (PheCode 189.21)|Jiang L|Nat Genet|2021-11-04","GCST90041901|Cancer code, self-reported: bladder cancer (UKB data field 20001_1035)|Jiang L|Nat Genet|2021-11-04","GCST90043933|ICD10 D09.0: Carcinoma in situ of bladder|Jiang L|Nat Genet|2021-11-04","GCST90077631|Bladder cancer (UKB data field 20001)|Backman JD|Nature|2021-10-18","GCST90079115|Malignant neoplasm of bladder, unspecified (UKB data field 40006)|Backman JD|Nature|2021-10-18","GCST90079116|Malignant neoplasm of bladder (UKB data field 40006)|Backman JD|Nature|2021-10-18","GCST90079133|Carcinoma in situ of bladder (UKB data field 40006)|Backman JD|Nature|2021-10-18","GCST90079611|ICD10 C67.9: Malignant neoplasm of bladder, unspecified|Backman JD|Nature|2021-10-18","GCST90079612|ICD10 C67: Malignant neoplasm of bladder|Backman JD|Nature|2021-10-18","GCST90081617|Bladder cancer (UKB data field 20001) (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083101|Malignant neoplasm of bladder, unspecified (UKB data field 40006) (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083102|Malignant neoplasm of bladder (UKB data field 40006) (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083119|Carcinoma in situ of bladder (UKB data field 40006) (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083597|ICD10 C67.9: Malignant neoplasm of bladder, unspecified (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90083598|ICD10 C67: Malignant neoplasm of bladder (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90140995|Overall survival in bladder cancer|Xin J|Nucleic Acids Res|2022-08-10","GCST90141012|Bladder cancer specific survival|Xin J|Nucleic Acids Res|2022-08-10","GCST90246031|ICD10 C67: Malignant neoplasm of bladder|Walters RG|Cell Genom|2023-07-20"]}]}